合欢花治疗广泛性焦虑障碍患者的效果及对SAS、HAMA评分的影响

Effect of Albizia julibrissin in the treatment of patients with generalized anxiety disorder and its influence on SAS and HAMA scores

目的研究广泛性焦虑障碍运用合欢花治疗的临床效果及对患者焦虑自评量表(SAS)与汉密尔顿焦虑量表(HAMA)评分的影响。方法60例广泛性焦虑障碍患者,运用随机分配方式分为A组与B组,各30例。A组患者使用合欢花进行治疗,B组患者运用劳拉西泮进行治疗。对比两组治疗效果、副作用发生率及治疗前后SAS、HAMA评分。结果治疗前,两组HAMA、SAS评分对比差异无统计学意义(P>0.05);治疗后,A组HAMA评分(18.13±1.26)分与SAS评分(50.13±1.51)分均明显低于B组的(30.56±1.98)、(65.61±1.99)分,差异具有统计学意义(P<0.05)。A组总有效率为96.67%(29/30),高于B组的80.00%(24/30),差异具有统计学意义(P<0.05)。A组副作用发生率为23.33%,低于B组的50.00%,差异具有统计学意义(P<0.05)。结论运用合欢花治疗广泛性焦虑障碍患者,可以明显提升整体治疗效果,有效改善患者SAS、HAMA评分,将副作用发生率控制在最小范围,值得在临床推广。

Objective To study the effect of Albizia julibrissin in the treatment of patients with generalized anxiety disorder and its influence on self-rating anxiety scale(SAS)and Hamilton anxiety scale(HAMA)scores.Methods A total of 60 patients with generalized anxiety disorder were randomly divided into group A and group B,with 30 cases in each group.Patients in group A were treated with Albizia julibrissin,and patients in group B were treated with lorazepam.The therapeutic effect,the incidence of side effects,and SAS and HAMA scores before and after treatment were compared between the two groups.Results Before treatment,there was no statistically significant difference in HAMA and SAS scores between the two groups(P>0.05).After treatment,the HAMA score(18.13±1.26)points and SAS score(50.13±1.51)points of group A were significantly lower than(30.56±1.98)and(65.61±1.99)points of group B,and the difference was statistically significant(P<0.05).The total effective rate in group A was 96.67%(29/30),which was higher than 80.00%(24/30)in group B,and the difference was statistically significant(P<0.05).The incidence of side effects in group A was 23.33%,which was lower than 50.00%in group B,and the difference was statistically significant(P<0.05).Conclusion Albizia julibrissin for patients with generalized anxiety disorder can significantly improve the overall treatment effect,effectively improve patients’SAS and HAMA scores,and control the incidence of side effects to a minimum,which is worthy of clinical promotion.